Spinal Muscular Atrophy (SMA) Treatmen Size, Share, Growth, and Forecast to 2025

Posted by rekha on September 20th, 2019

Precision Business Insights (PBI) in its report titled “Global Spinal Muscular Atrophy (SMA) Treatment market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2024” assesses the market performance over seven years forecast period over 2018-2024. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global spinal muscular atrophy (SMA) treatment market was valued at US$ XX Mn in 2018 and increasing at a significant CAGR over the forecast timeframe owing to surge in the incidence of inflammatory and pain mediated diseases, headaches and rate of incidence of diseases like cancer, arthritis like diseases which involve severe pain, its nature of pain reduction with less dependence on opioids, growing healthcare awareness and health care spending, increasing number of manufacturing companies, and rise in the number of product approvals are expected to drive the global spinal muscular atrophy (SMA) treatment market. However, factors such as increased market competition, regulations of governments, and laws like drug price control order which restrict the price of product in the market are anticipated to hinder the revenue share of global spinal muscular atrophy (SMA) treatment market.

Global spinal muscular atrophy (SMA) treatment market segmented on the basis of treatment, route of administration, type of disease and Geography.

For request sample : https://www.precisionbusinessinsights.com/request-sample?product_id=37340

Type 1 Spinal Muscular Atrophy (SMA) Treatment Dominates the Global Spinal Muscular Atrophy (SMA) Treatment market

Based on type of disease, global spinal muscular atrophy (SMA) treatment market segmented into Type 1, Type 2, Type 3, and Type 4. Among them, type 1 spinal muscular atrophy treatment dominated the global spinal muscular atrophy (SMA) treatment market in 2018 and estimated to dominate over the forecast period, as it is one of the most common forms of SMA and the increasing incidences of this type and focus of companies on developing drugs for SMA treatment and increased demand in the market are surge the market over the forecast years.

North America Leads the Global Spinal Muscular Atrophy (SMA) Treatment market

PBI’s global spinal muscular atrophy (SMA) treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to advance healthcare system, Enhanced R&D activities, approved drug for the treatment of SMA (Spinraza), presence of major market player Biogen Inc. in US, high disposable income, and rise in the adaptation of spinraza are propel the market. Asia Pacific spinal muscular atrophy (SMA) treatment market projected to exhibit significant growth due to owing to increase in research and development, rapidly developing health infrastructure in countries such as China and India, increasing number of initiatives to improve the access tSMA therapies are expected to enhance the market.

Launch of newer formulation products, frequent product approvals, and strategic alliances are the key strategies adopted by market players

Global spinal muscular atrophy (SMA) treatment market further reveals that the key players increasingly adopting strategies such as launch of newer technologies of needle free injector products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region.

Key player’s profiles in the report are

• Biogen
• Ionis Pharmaceuticals, Inc.
• F. Hoffmann - La Roche Ltd
• Avexis, Inc.
• Novartis AG
• Cytokinetics, Inc.
• Voyager Therapeutics

Detailed Segmentation

By Treatment

• Gene Therapy
• Drug

By Route of administration

• Oral
• Intrathecal

 By Disease type

• Type 1
• Type 2
• Type 3
• Type 4

Geography

• North America
  • U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/spinal-muscular-atrophy-sma-treatment-market/